Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1996-10-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM960482IPMID 8863790PMCID PMC10791485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.

  1996cited by this paper
• Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.

  1996cited by this paper
• Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists.

  1996cited by this paper
• A SURVEY OF NONXANTHINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS.

  1996cited by this paper
• Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists.

  1996cited by this paper
• Mast cell degranulation following adenosine A3 receptor activation in rats.

  1996cited by this paper
• Interactions of flavonoids and other phytochemicals with adenosine receptors.

  1996cited by this paper
• Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition.

  1996cited by this paper
• 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells.

  1995cited by this paper
• A3-adenosine receptors: design of selective ligands and therapeutic prospects.

  1995cited by this paper
• Adenosine receptor subtypes: characterization and therapeutic regulation.

  1995cited by this paper
• A role for mast cells in adenosine A3 receptor‐mediated hypotension in the rat

  1995cited by this paper
• Identification of Domains of the Human A1 Adenosine Receptor That Are Important for Binding Receptor Subtype-selective Ligands Using Chimeric A1/A2a Adenosine Receptors (*)

  1995cited by this paper
• Species differences in ligand affinity at central A3‐adenosine receptors

  1994cited by this paper
• Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

  1994cited by this paper
• Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.

  1994cited by this paper
• A binding site model and structure-activity relationships for the rat A3 adenosine receptor.

  1994cited by this paper
• 125I-4-aminobenzyl-5'-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor.

  1994cited by this paper
• Adenosine A3 receptor stimulation and cerebral ischemia.

  1994cited by this paper
• A role for central A3‐adenosine receptors

  1993cited by this paper
• Molecular cloning and characterization of the human A3 adenosine receptor.

  1993cited by this paper
• Characterization of human striatal A2-adenosine receptors using radioligand binding and photoaffinity labeling.

  1992cited by this paper
• Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

  1992cited by this paper
• Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex.

  1991cited by this paper
• [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.

  1989cited by this paper
• Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists.

  1988cited by this paper
• Characterization of adenosine receptors in rat brain by (−)[3H]N6-phenylisopropyladenosine

  1980cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Development of 9-cinnamyl-9H-purine derivatives as potent anticancer agents through inactivation of NF-κb/p65 and p-STAT1 signaling pathways: Discovery of a new template for adenosine receptor.

  2025cites this paper
• Adenosine receptors in GtoPdb v.2025.4

  2025cites this paper
• Assay-Dependent Inverse Agonism at the A3 Adenosine Receptor: When Neutral Is Not Neutral.

  2023cites this paper
• METHODS OF SYNTHESIS OF QUINAZOLINES AND THEIR CONDENSED ANALOGUES – POTENTIAL ANTI-INFLAMMATORY AGENTS (REVIEW)

  2023cites this paper
• Species dependence of A3 adenosine receptor pharmacology and function

  2022cites this paper
• Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.

  2022cites this paper
• Phenotypic Discovery of Triazolo[1,5-c]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype.

  2022cites this paper
• Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands.

  2022cites this paper
• Magnetically Separable Fe3O4@poly(m‐phenylenediamine)@Cu2O Nanocatalyst for the Facile Synthesis of 5‐phenyl‐[1,2,3]triazolo[1,5‐c]quinazolines

  2022cites this paper
• Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists

  2021cites this paper
• An overview of triazoloquinazolines: Pharmacological significance and recent developments.

  2021cites this paper
• Adenosine receptors in GtoPdb v.2021.2

  2021cites this paper
• Directed Search of Anti-inflammatory Agents Among (3H-Quinazoline-4-ylidene)hydrazides of N-protected Amino acids and their Heterocyclization Products

  2020cites this paper
• A Comparison in the Use of the Crystallographic Structure of the Human A1 or the A2A Adenosine Receptors as a Template for the Construction of a Homology Model of the A3 Subtype

  2019cites this paper
• Adenosine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents.

  2019cites this paper
• A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy

  2018cites this paper
• Medicinal Chemistry of the A 3 Adenosine Receptor

  2018cites this paper
• Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes.

  2017cites this paper
• cascade and signals through arachidonic acid adenosine receptor mediates human chorionic 2B

  2016cites this paper
• Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation.

  2015cites this paper
• 1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A₃ receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.

  2015cites this paper
• The A3 Adenosine Receptor: History and Perspectives

  2015cites this paper
• Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.

  2014cites this paper
• Organoruthenium antagonists of human A₃ adenosine receptors.

  2013cites this paper
• Characterization of P1 (Adenosine) Purinoceptors

  2013cites this paper
• The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches

  2013cites this paper
• A3 adenosine receptor: homology modeling and 3D-QSAR studies.

  2013cites this paper
• Recent advances on QSAR-based profiling of agonist and antagonist A3 adenosine receptor ligands.

  2013cites this paper
• The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors

  2013cites this paper
• Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.

  2012cites this paper
• Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists

  2012cites this paper
• The glucocorticoid dexamethasone programs human dendritic cells for enhanced phagocytosis of apoptotic neutrophils and inflammatory response

  2012influential citation
• Comparative pharmacophore modeling of human adenosine receptor A1 and A3 antagonists

  2012cites this paper
• The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction.

  2012cites this paper
• Molecular Modelling Studies on Molecular Pathways Related to Tumorigenesis in the Discovery of New Lead Compounds.

  2012cites this paper
• Recent advances on A₃ adenosine receptor antagonists by QSAR tools.

  2012cites this paper
• Adenosine in the inflamed gut: a Janus faced compound.

  2011cites this paper
• Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.

  2011cites this paper
• Electronic Structure of some A3 Adenosine-Receptor Antagonist - - A Structure Activity Relationship

  2011cites this paper
• A2A receptor ligands: past, present and future trends.

  2010cites this paper
• Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.

  2010cites this paper
• The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.

  2010cites this paper
• A3 Adenosine Receptor Antagonists: History and Future Perspectives

  2010cites this paper
• Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

  2009influential citation
• CKIε/δ-dependent phosphorylation is a temperature-insensitive, period-determining process in the mammalian circadian clock

  2009cites this paper
• Purines as Transmitter Molecules: Electrophysiological Studies on Purinergic Signalling in Different Cell Systems

  2009influential citation
• Recent developments in adenosine A2A receptor ligands.

  2009cites this paper
• Caffeine Modulates TNF-α Production by Cord Blood Monocytes: The Role of Adenosine Receptors

  2009cites this paper
• Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists.

  2008cites this paper
• Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility.

  2008cites this paper
• Adenosine A1 and A3 Receptor Agonists Inhibit Nonadrenergic, Noncholinergic Relaxations in the Guinea Pig Isolated Trachea

  2008cites this paper
• Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists.

  2008cites this paper
• Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we?

  2008cites this paper
• 1-Phenyl-6,7,8,9-hexahydro-1H,5H-cyclohepta[1′,2′:2,3]pyrido[6,5-c]pyrazol-4-amine: a new tacrine analogue

  2008cites this paper
• Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.

  2008cites this paper
• Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists.

  2008cites this paper
• A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.

  2008cites this paper
• Bicyclic 5-6 systems with one bridgehead (ring junction) nitrogen atom: Three extra heteroatoms 2:1

  2008cites this paper
• Synthesis of 2H-3,1-pyrazolo[3,4-e]oxazines via a new conversion of Friedländer reaction

  2007cites this paper
• [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor.

  2007cites this paper
• New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

  2007cites this paper
• Highlights on the Development of A2A Adenosine Receptor Agonists and Antagonists

  2007cites this paper
• 5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.

  2007cites this paper
• The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis

  2007cites this paper
• A-2B Adenosine Receptor

  2007cites this paper
• Role of S-adenosylhomocysteine hydrolase in adenosine-induced apoptosis in HepG2 cells.

  2007cites this paper
• Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.

  2006cites this paper
• Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

  2006cites this paper
• Agent prophylactique et/ou thérapeutique pour troubles moteurs

  2006cites this paper
• Triazoloquinazolines as Human A3 Adenosine Receptor Antagonists: A QSAR Study

  2006cites this paper
• Structure‐affinity relationships of adenosine A2B receptor ligands

  2006cites this paper
• Progress in the pursuit of therapeutic adenosine receptor antagonists

  2006cites this paper
• A 3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA 1 hippocampus in vitro

  2006cites this paper
• Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors.

  2006cites this paper
• Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors.

  2006cites this paper
• The synthesis of highly potent, selective, and water-soluble agonists at the human adenosine A3 receptor.

  2006cites this paper
• Quantitative structure activity relationships as useful tools for the design of new adenosine receptor ligands. 1. Agonist.

  2006cites this paper
• A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro

  2006cites this paper
• Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure–activity profile

  2006cites this paper
• Ligands for A2B adenosine receptor subtype.

  2006cites this paper
• Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists.

  2005cites this paper
• Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A(3) adenosine receptor antagonists.

  2005cites this paper
• Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine ligands, new tools to characterize A3 adenosine receptors in human tumor cell lines.

  2005cites this paper
• 2-aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists.

  2005cites this paper
• A2B adenosine receptor mediates human chorionic vasoconstriction and signals through arachidonic acid cascade.

  2005cites this paper
• Nuevos compuestos de timina y 6-aminoauracilo : síntesis y evaluación frente a distintas dianas terapéuticas

  2004cites this paper
• Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands.

  2004cites this paper
• Signalisation du récepteur des lymphocytes T (TCR) dans le thymus : interactions entre différentes voies MAPK (mitogen activated protein kinase) et régulation par l'adénosine

  2004cites this paper
• Regulation of Adenosine Receptor Subtypes during Cultivation of Human Monocytes: Role of Receptors in Preventing Lipopolysaccharide-Triggered Respiratory Burst

  2004cites this paper
• Structure-activity relationships of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists.

  2004cites this paper
• Recent developments in the field of A3 adenosine receptor antagonists

  2003cites this paper
• Medicinal chemistry of A2A adenosine receptor antagonists.

  2003cites this paper
• Medicinal chemistry of adenosine A3 receptor ligands.

  2003cites this paper
• 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities

  2003cites this paper
• 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors.

  2003cites this paper
• Chapter 13. A3 Adenosine Receptors.

  2003cites this paper
• Antagonism of adenosine receptors by caffeine and caffeine metabolites in equine forebrain tissues.

  2003cites this paper
• Recent developments in the field of A2A and A3 adenosine receptor antagonists.

  2003cites this paper
• A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

  2002cites this paper